Key result
R-alpha lipoic acid linked to ~43% lower SCD in geriatric T2D patients with dysautonomia.
Why the study?
Diabetes and autonomic neuropathy increase the risk of sudden cardiac death, and oxidative stress is a major cause of diabetic autonomic neuropathy.
Does (r) Alpha Lipoic Acid reduce Sudden Cardiac Death in geriatric type II diabetes mellitus patients with autonomic neuropathy?
Cohort (n=133)
Open-label
No
Does (r) Alpha Lipoic Acid reduce Sudden Cardiac Death in geriatric type II diabetes mellitus patients with autonomic neuropathy?
(r)-Alpha Lipoic Acid supplementation is associated with a significant reduction in sudden cardiac death and improved autonomic function in older patients with type II diabetes and autonomic neuropathy.
Answers are grounded in this paper and cite their sources.
Antioxidant therapy may improve autonomic balance in DAN; hypothesis-generating for SCD reduction, needs prospective confirmation.
Background: Diabetes carries a two-fold risk of Sudden Cardiac Death (SCD). Diabetic Autonomic Neuropathy (DAN), often progressing to Cardiovascular Autonomic Neuropathy (CAN, critically low parasympathetic tone [P]), increases death 3.5-fold over 5 years, half sudden or non-renal. Oxidative stress is a major cause of DAN. Also, increased sympathetic tone (S), High Sympathovagal Balance [SB>2.5] increases SCD risk. Objective: Dysautonomic diabetic II patients were treated with the antioxidant (r) Alpha Lipoic Acid (ALA), autonomic function followed, and Sudden Death (SD) compared to untreated patients. Methods: 133 patients (mean age 66y/o) with DAN or CAN, diagnosed using the ANX 3.0 Autonomic Monitor (Physio PS, Inc., Atlanta, GA) was offered (r)-ALA: 83 agreed (Group 1), and 50 refused (Group 2). P and S were re-measured up to 3 times/yr (mean f/u 6.31 yrs); SCDs were recorded. Results: A 43% Relative Risk Reduction (RRR) in SCD occurred with (r)-ALA (25% SCD Group 1 vs. 44% SCD Group 2, p=0.0076). Initial to final patients with high SB or CAN were 21.7%-12% (p=0.010), 10.8%-15.7% (p=0.045), Group 1 vs. 24%-22% (p=ns), 6%-12% (p=0.083), Group 2. Only Group 1 survivors increased mean resting P. The progressive increase in P’s decline, increasing CAN risk, in the other patients correlated with mortality (p<0.001) and (r) ALA dose. Initially, Group 1 had insignificantly less high SB (p=0.449) and significantly more CAN (p=0.013) vs. Group 2. Finally, Group 1 had significantly less high SB (p=0.0967) vs. Group 2, also improving to insignificantly more CAN (p=0.261). Conclusion: (r)-ALA was associated with a 43% RRR of SCD and favorable P and S changes.
No takes yet. Share an insight, caveat, or question.
Murray et al. (2020) conducted a cohort in Type 2 Diabetes Mellitus with dysautonomia (n=133). (r) Alpha Lipoic Acid vs. No (r) Alpha Lipoic Acid was evaluated on Sudden Cardiac Death (SCD) (RRR 43%, p=0.0076). (r)-Alpha Lipoic Acid reduced sudden cardiac death by 43% compared to no treatment in geriatric patients with type 2 diabetes and dysautonomia.
Synapse has enriched 10 related papers. Consider them for comparative context: